Nectar Lifesciences Limited announced a significant strategic move following its board meeting on March 2, 2026. The company has decided to acquire 100% of the paid-up equity share capital of Avensis Exports Private Limited (AEPL), a company primarily engaged in the real estate business. This acquisition is aimed at diversifying Nectar Lifesciences' business portfolio and enabling its entry into the real estate sector. AEPL, incorporated on October 16, 2007, has paid-up equity share capital of ₹8,00,000 and reported nil turnover in the last three financial years. The cost of acquisition for 100% shareholding is ₹24,96,000, with the company acquiring 80,000 equity shares at ₹31.20 per share. The acquisition is expected to be completed within one month and is not considered a related party transaction. In addition to the acquisition, the board also approved a change in the Company's Registrar and Share Transfer Agent (RTA). The RTA services will transition from M/s. KFin Technologies Limited to M/s. Alankit Assignments Limited. This change is driven by the objective to reduce service costs, enhance operational efficiency, and improve investor service experience. KFin Technologies will continue to serve until the data transition and other related procedures are completed. The board meeting commenced at 4:00 P.M. IST and concluded at 4:30 P.M. IST.
